Delcath Systems to Be Featured on Health Uncensored with Dr. Drew in Segment on Precision Oncology for Metastatic Liver Cancer
Delcath Systems, Inc., an interventional oncology company focused on developing and commercializing treatments for primary and metastatic liver cancers, announced that it will be featured in an upcoming episode of Health Uncensored with Dr. Drew. The segment, titled “Precision Oncology: Changing the Game for Metastatic Liver Cancer,” will examine advances in liver-directed cancer treatment, with particular attention to percutaneous hepatic perfusion (PHP) and the role of specialized medical technology in delivering chemotherapy directly to the liver.
The program is scheduled to air nationally on Sunday, November 15, 2026, on FOX Business Network. A podcast version of the segment is also expected to become available following the television broadcast, giving audiences an additional opportunity to access the discussion.
The feature will include perspectives from Gerard Michel, Chief Executive Officer of Delcath Systems, and Dr. Sachin Modi, Consultant Interventional Radiologist at University Hospital Southampton in the United Kingdom. The discussion will explore how PHP is used in the treatment of liver cancer, how the procedure works and how Delcath’s Hepatic Delivery System supports the delivery of high-dose chemotherapy to the liver while limiting patients’ exposure to the treatment throughout the rest of the body.
The program will also take viewers inside a treatment center to provide a closer look at the clinical environment in which the procedure is performed. University Hospital Southampton has completed more than 500 PHP procedures using Delcath’s Hepatic Delivery System, demonstrating the center’s substantial experience with this liver-directed treatment approach.
Television Segment to Highlight Advances in Precision Oncology
The upcoming Health Uncensored with Dr. Drew segment will focus on the evolving role of precision oncology in addressing metastatic liver cancer. Precision oncology involves selecting and delivering treatments based on the characteristics of a patient’s disease and the biological or clinical factors that may influence treatment response.
Liver cancer presents significant treatment challenges, particularly when tumors originate elsewhere in the body and spread to the liver. Metastatic liver tumors can arise from several types of cancer, and treatment decisions may depend on the primary cancer, the extent of liver involvement, the patient’s overall health and the availability of appropriate treatment options.
For certain patients, treatments directed specifically at the liver may provide an alternative or additional approach to managing disease. These therapies are designed to concentrate treatment within the affected organ rather than relying exclusively on systemic administration, which exposes the entire body to medication.
The television feature will examine PHP as one such liver-directed approach. Through the participation of Delcath’s leadership and an experienced interventional radiologist, the segment aims to explain the technology and clinical procedure involved in delivering chemotherapy to patients with liver cancer.
The program’s treatment-center coverage is expected to offer viewers a practical perspective on how the procedure is incorporated into clinical care. This includes the specialized equipment and medical expertise required to perform PHP and the importance of coordinating treatment in an experienced hospital setting.
Understanding Percutaneous Hepatic Perfusion
Percutaneous hepatic perfusion is a minimally invasive, liver-directed treatment approach designed to deliver high concentrations of chemotherapy directly to the liver. The procedure is intended to expose tumors within the liver to high-dose chemotherapy while limiting the amount of chemotherapy that reaches the rest of the body’s systemic circulation.
During PHP, chemotherapy is delivered through the liver’s blood supply. The treatment process incorporates a specialized filtration system that collects and filters blood leaving the liver before returning it to the patient’s systemic circulation.
This filtration step is an important component of the procedure. When chemotherapy is administered directly into the liver, some of the drug may leave the organ through the hepatic venous circulation. Without an appropriate method of controlling systemic exposure, chemotherapy could circulate throughout the body and affect tissues and organs beyond the intended treatment area.
PHP addresses this challenge by filtering the blood before it returns to the general circulation. The approach is designed to reduce systemic exposure to chemotherapy while enabling the delivery of a high drug concentration to the liver.
The procedure requires specialized equipment, trained medical professionals and a coordinated clinical environment. Interventional radiologists and other members of the treatment team play important roles in carrying out the procedure and monitoring patients throughout the treatment process.
Delcath’s Hepatic Delivery System Supports Liver-Directed Treatment
Delcath’s Hepatic Delivery System is designed for use in the PHP procedure. The system supports the delivery of high-dose chemotherapy to the liver and the filtration of blood before it is returned to systemic circulation.
The technology is central to the treatment approach that will be discussed in the television segment. By combining targeted chemotherapy administration with blood filtration, the system is intended to help limit the amount of chemotherapy circulating beyond the liver.
For patients with cancers involving the liver, this approach represents a specialized treatment strategy that focuses on the affected organ. It is particularly relevant to interventional oncology, a field that uses image-guided and minimally invasive procedures to diagnose and treat cancer.
Interventional oncology techniques can provide treatment options that differ from conventional systemic therapies or surgical approaches. These procedures often require specialized devices and clinical expertise, making the experience of the treating institution an important consideration.
The upcoming program will provide an opportunity to explain how Delcath’s technology is used in clinical practice and how PHP fits into the broader landscape of treatment options for metastatic liver cancer.
University Hospital Southampton Highlights Extensive PHP Experience
Dr. Sachin Modi, Consultant Interventional Radiologist at University Hospital Southampton in the United Kingdom, will be featured in the segment alongside Delcath CEO Gerard Michel.
University Hospital Southampton has performed more than 500 PHP procedures using Delcath’s Hepatic Delivery System. This experience provides an important clinical perspective on the implementation of liver-directed perfusion treatment within a specialist hospital setting.
The center’s experience also offers an opportunity to demonstrate the practical considerations involved in performing PHP. Such procedures require careful planning, specialized equipment and coordination among clinical teams to ensure that chemotherapy delivery and blood filtration are carried out as intended.
The program will take viewers inside a treatment center, helping audiences understand the clinical environment in which the procedure takes place. By including the perspective of a practicing interventional radiologist, the feature is expected to connect the technology with its application in patient care.
The participation of Dr. Modi will also bring attention to the role of experienced clinicians in adopting and delivering specialized interventional oncology procedures. As hospitals evaluate advanced treatment technologies, clinical experience and the ability to integrate complex procedures into established care pathways remain important considerations.
Delcath Leadership to Discuss the Company’s Technology
Gerard Michel, Chief Executive Officer of Delcath Systems, will also participate in the segment. His involvement will provide the company’s perspective on the development and use of its Hepatic Delivery System in liver-directed cancer treatment.
As an interventional oncology company focused on primary and metastatic liver cancers, Delcath is working in a specialized area of cancer care where targeted treatment delivery and procedural technology play significant roles.
The discussion on Health Uncensored with Dr. Drew will provide a platform to explain the principles behind PHP and the technology used to perform the procedure. It will also help introduce viewers to the potential role of liver-directed treatment approaches in managing cancers that affect the liver.
The feature is particularly relevant because metastatic liver cancer can involve complex treatment decisions. Depending on the patient’s condition and disease characteristics, clinicians may consider different treatment strategies, including systemic therapy, surgery, radiation-based approaches and liver-directed procedures.
PHP represents one approach within this broader treatment landscape. Its design focuses on delivering chemotherapy to the liver while filtering the blood to reduce systemic exposure. The upcoming segment will explain how this process is performed and how Delcath’s system supports the procedure.
Broadcast and Podcast Availability
The segment will be included in Health Uncensored with Dr. Drew, in an episode titled “Mario & Courtney Lopez: Health From the Inside Out.” The program will air on FOX Business Network on Sunday, November 15, 2026.
The broadcast details are as follows:
- Program: Health Uncensored with Dr. Drew
- Episode title: Mario & Courtney Lopez: Health From the Inside Out
- Segment title: Precision Oncology: Changing the Game for Metastatic Liver Cancer
- Network: FOX Business Network
- Air date: Sunday, November 15, 2026
- Broadcast time: 5:30 p.m. ET / 2:30 p.m. PT
Following the television broadcast, episodes of Health Uncensored with Dr. Drew are expected to be available through the program’s website, HealthUncensoredTV.com, and its YouTube channel. A podcast featuring the discussion is also expected to be released after the television airing.
These additional distribution channels will allow viewers who miss the original broadcast to access the program later.
Raising Awareness of Liver-Directed Cancer Treatment
Delcath’s participation in the program reflects an opportunity to increase awareness of specialized treatment approaches for primary and metastatic liver cancers. By presenting PHP through both company and clinical perspectives, the segment will explain how targeted chemotherapy delivery and blood filtration are combined in a single treatment procedure.
The inclusion of University Hospital Southampton’s experience with more than 500 procedures will also highlight the importance of clinical expertise in delivering specialized interventional oncology treatments.
As cancer care continues to incorporate increasingly targeted approaches, technologies designed to deliver treatment directly to affected organs may play an important role in the development of new therapeutic strategies. PHP is one example of this approach, using a liver-focused delivery method intended to limit chemotherapy exposure elsewhere in the body.
Through the upcoming Health Uncensored with Dr. Drew feature, Delcath aims to bring greater visibility to its Hepatic Delivery System, the clinical application of PHP and the broader role of precision oncology in treating metastatic liver cancer. The discussion featuring Gerard Michel and Dr. Sachin Modi will provide viewers with an overview of the procedure, its supporting technology and its use at an experienced treatment center.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) in the United States and CHEMOSAT® Hepatic Delivery System for Melphalan in Europe, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure during a percutaneous hepatic perfusion procedure.
HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.